Executives of major pharmaceutical companies warned the European Union that they’re likely to take the US’ side amid the threat of new tariffs.

The state of the US biosimilar market isn't as healthy as it should be despite significant advances in the past decade, ...

The Trump administration on Tuesday said it will challenge a federal judge’s order that blocks its planned 15% rate limit on ...

FDA staff cuts could trigger user fee clawback mechanism, but experts including Patrick Frey and David Risinger say immediate ...

Novo Nordisk focused on a unique argument in federal appeals court on Tuesday in a case that will consider the extent to ...

The Trump administration will hike payments to Medicare Advantage insurers by more than $25 billion next year, according to ...

Cartesian Therapeutics reports sustained benefits of Descartes-08 CAR-T therapy in generalized myasthenia gravis patients, ...

A scrappy team of drug developers has come together to create new medicines for patients with autoimmune diseases and allergies. They're going after the bustling subfield of Graves' disease and ...

A congressional commission is calling for at least a $15 billion federal investment in America’s biotechnology sector, ...

The government said it 'may consider future policy options' for anti-obesity medications, after declining to finalize a Biden ...

A federal judge in Minnesota knocked down challenges from two drugmakers against a state law that the companies argued overly expanded the scope of the government's 340B drug discount program.

PureTech Health, a Boston biopharma company that has created drug developers like Karuna Therapeutics and Seaport ...